• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Biochem J . Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp14 RNA cap methyltransferase

tetano

Editor, Senior Moderator
Biochem J


. 2021 Jul 16;478(13):2481-2497.
doi: 10.1042/BCJ20210219.
Identifying SARS-CoV-2 antiviral compounds by screening for small molecule inhibitors of Nsp14 RNA cap methyltransferase


Souradeep Basu[SUP] #[/SUP][SUP] 1 [/SUP], Tiffany Mak[SUP] #[/SUP][SUP] 1 [/SUP], Rachel Ulferts[SUP] 2 [/SUP], Mary Wu[SUP] 3 [/SUP], Tom Deegan[SUP] 4 [/SUP], Ryo Fujisawa[SUP] 4 [/SUP], Kang Wei Tan[SUP] 5 [/SUP], Chew Theng Lim[SUP] 5 [/SUP], Clovis Basier[SUP] 1 [/SUP], Berta Canal[SUP] 5 [/SUP], Joseph F Curran[SUP] 1 [/SUP], Lucy S Drury[SUP] 5 [/SUP], Allison W McClure[SUP] 5 [/SUP], Emma L Roberts[SUP] 1 [/SUP], Florian Weissmann[SUP] 5 [/SUP], Theresa U Zeisner[SUP] 1 [/SUP], Rupert Beale[SUP] 2 [/SUP], Victoria H Cowling[SUP] 6 [/SUP], Michael Howell[SUP] 3 [/SUP], Karim Labib[SUP] 4 [/SUP], John F X Diffley[SUP] 5 [/SUP]



Affiliations

Abstract

The COVID-19 pandemic has presented itself as one of the most critical public health challenges of the century, with SARS-CoV-2 being the third member of the Coronaviridae family to cause a fatal disease in humans. There is currently only one antiviral compound, remdesivir, that can be used for the treatment of COVID-19. To identify additional potential therapeutics, we investigated the enzymatic proteins encoded in the SARS-CoV-2 genome. In this study, we focussed on the viral RNA cap methyltransferases, which play key roles in enabling viral protein translation and facilitating viral escape from the immune system. We expressed and purified both the guanine-N7 methyltransferase nsp14, and the nsp16 2'-O-methyltransferase with its activating cofactor, nsp10. We performed an in vitro high-throughput screen for inhibitors of nsp14 using a custom compound library of over 5000 pharmaceutical compounds that have previously been characterised in either clinical or basic research. We identified four compounds as potential inhibitors of nsp14, all of which also showed antiviral capacity in a cell-based model of SARS-CoV-2 infection. Three of the four compounds also exhibited synergistic effects on viral replication with remdesivir.

Keywords: coronavirus; covid-19; mRNA cap; methyltransferase.
 
Back
Top Bottom